MissionIR News - FluoroPharma Medical Expands Global Patent Position with Patent Rights for BFPET in Australia

Share Article

Novel imaging agent helps detect cardiovascular disease

MissionIR would like to highlight FluoroPharma (OTCBB: FPMI), a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. FluoroPharma's goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

In the company’s news yesterday,

FluoroPharma Medical announced that BFPET, its imaging agent for measuring cardiovascular blood flow, has been granted patent rights in Australia. BFPET is a novel cardiovascular blood flow imaging agent that, when used in conjunction with stress-testing, identifies patients with suspected and proven coronary artery disease (CAD). The patent expiration date is 2025.

Symptomatic coronary artery disease (CAD) affects millions of patients worldwide and, according to the World Health Organization, cardiovascular diseases are the leading causes of death and disability in the world. The demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic CAD.

“Phase I clinical trial for BFPET indicates that the compound has an acceptable dosimetry and safety profile and provides high resolution images of the heart,” commented Dr. David Elmaleh, FluoroPharma’s Chairman of the Board of Directors and inventor of the technology. “Since BFPET has the potential to be a more sensitive marker than the currently available blood flow agents, we believe that BFPET will have strong advantages over currently marketed products in the detection of acute and chronic ischemia.”

“The future for diagnostic imaging procedures with higher specificity is extremely promising as they provide early and more accurate information to enable more effective treatment and follow-up of its efficacy,” added Thijs Spoor, FluoroPharma’s President and Chief Executive Officer. “We look at this as an evolution to more effective and efficient care. Early treatment means saving the patient from long and expensive hospital stays, which results in less time away from family and work.”

In November of last year, FluoroPharma announced that it had been granted patent rights in China for BFPET and another imaging agent, AZPET, for imaging of Alzheimer’s disease. In addition to Australia and China, patents related to FluoroPharma’s portfolio of imaging compounds have been issued in the United States, Europe, Japan, Canada, Finland, Portugal, Ireland, and Mexico.

Today’s announcement enhances FluoroPharma’s position in the Pacific Rim and strengthens its growing patent estate, further validating the importance and value of FluoroPharma’s technology in important growth markets where diagnostic imaging is playing an increasingly significant role in the early detection of disease.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

MissionIR Communications
Visit website